Sabril<\/strong> (generic name vigabatrin<\/strong>) is an anticonvulsant medication that works by inhibiting GABA\u2011transaminase, increasing GABA<\/strong>\u2014an inhibitory neurotransmitter\u2014to stabilize abnormal electrical activity in the brain\u00a0It is available as 500\u202fmg tablets<\/strong> and powder packets<\/strong> for oral solution.<\/span><\/p>\n Adjunctive<\/strong> treatment for patients aged 2\u202fyears and older whose seizures haven\u2019t responded to other medications<\/span>.<\/p>\n<\/li>\n Not recommended<\/strong> as first-line therapy<\/span>.<\/p>\n<\/li>\n<\/ul>\n Monotherapy<\/strong> in babies aged 1\u202fmonth to 2\u202fyears, when benefits outweigh vision risks<\/span>.<\/p>\n<\/li>\n Demonstrated reduction or elimination of spasms in clinical trials<\/span>.<\/p>\n<\/li>\n<\/ul>\n By irreversibly inhibiting GABA transaminase<\/strong>, vigabatrin elevates GABA levels in the brain, reducing seizure activity<\/span> . It does not directly bind GABA receptors.<\/span><\/p>\n Initial<\/strong>: 1,000\u202fmg\/day (500\u202fmg twice daily).<\/span><\/p>\n<\/li>\n Target<\/strong>: 3,000\u202fmg\/day (1,500\u202fmg twice daily).<\/span><\/p>\n<\/li>\n Max<\/strong>: Studies show no extra benefit beyond 3,000\u202fmg; increased adverse events at 6,000\u202fmg\/day<\/span><\/p>\n<\/li>\n<\/ul>\n Dosage based on body weight<\/strong>, adjusted weekly<\/span>.<\/p>\n<\/li>\n<\/ul>\n
\n2. Approved Uses<\/h2>\n
A. Refractory Complex Partial Seizures<\/h3>\n
\n
B. Infantile Spasms (West Syndrome)<\/h3>\n
\n
\n3. How It Works<\/h2>\n
\n4. Dosage Guidelines<\/h2>\n
A. Adults (\u2265\u202f17 years) with Complex Partial Seizures<\/h3>\n
\n
B. Children (2\u201316 years) with Complex Partial Seizures<\/h3>\n
\n
C. Infantile Spasms (1\u202fmonth\u20132\u202fyears)<\/h3>\n